LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Codexis, Inc. (NASDAQ: CDXS), a leader in biocatalysis focused on using their enzyme engineering platform to streamline chemical transformations for the pharmaceutical and fine chemicals industries. Biocatalysis is a low cost, safe, and environmentally friendly alternative to conventional chemistry approaches for manufacturing drugs. Codexis integrates itself early in the drug discovery process by offering comprehensive kits of enzymes for customers to sample, and specializes in customizing enzymes using their proprietary CodeEvolver® technology to rapidly deliver the desired process improvements. The Company has helped transform the manufacturing processes for several leading drugs, and has won three Presidential Green Chemistry Challenge Awards, which is more than any other company other than the manufacturing giants Dow, BASF, and Merck, who have each also won three.
"Codexis has proven their ability to create biocatalysts that improve product yields, reduce waste, eliminate process steps, and lower manufacturing costs broadly across the universe of pharmaceutical companies," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "Leading pharmaceutical companies are beginning to recognize the value of biocatalysis and are increasingly incorporating Codexis technology in all stages of drug development from discovery to commercialization."
Codexis has sold enzyme kits to 15 of the top 20 pharmaceutical companies by revenue and has agreements with 7 of the top 10 pharmaceutical companies to implement biocatalysis strategies for drug manufacturing. The Company works at all stages of development from preclinical candidates to already approved products. Revenue is generated by selling biocatalysts or chemical intermediates, creating customized enzymes, as well as licensing deal royalties, milestones, and fees. Codexis has a long-standing partnership with Merck for the development and supply of biocatalysts across a broad range of drug manufacturing programs.
In a 30 page Initiation Report by LifeSci Advisors, we explain the market opportunity for biocatalysis in the pharmaceutical industry. The report discusses Codexis' CodeEvolver Technology and how it can rapidly transform enzymes to improve drug manufacturing processes. We also explore specific examples of how Codexis has created biocatalysts for the manufacture of successful drugs.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
Important Disclosures:
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com
Codexis Contact:
David O'Toole
Phone: (650)-421-8152
Email: ir@codexis.com
SOURCE: LifeSci Advisors
Associated Documentation:
Link to submission on http://www.eteligis.com
Lifesci_4-17-2014_ELS_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment